KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Deferred Taxes: 2018-2024

Historic Deferred Taxes for Xenon Pharmaceuticals (XENE) over the last 7 years, with Dec 2024 value amounting to -$8.9 million.

  • Xenon Pharmaceuticals' Deferred Taxes fell 117.70% to -$701,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.7 million, marking a year-over-year decrease of 2266.37%. This contributed to the annual value of -$8.9 million for FY2024, which is 2935.62% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Deferred Taxes stood at -$8.9 million for FY2024, which was down 2,935.62% from -$292,000 recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Deferred Taxes peaked at $58,000 during FY2021, and registered a low of -$8.9 million during FY2024.
  • Moreover, its 3-year median value for Deferred Taxes was -$292,000 (2023), whereas its average is -$3.1 million.
  • Its Deferred Taxes has fluctuated over the past 5 years, first soared by 120.35% in 2021, then crashed by 2,935.62% in 2024.
  • Xenon Pharmaceuticals' Deferred Taxes (Yearly) stood at -$285,000 in 2020, then skyrocketed by 120.35% to $58,000 in 2021, then tumbled by 175.86% to -$44,000 in 2022, then slumped by 563.64% to -$292,000 in 2023, then crashed by 2,935.62% to -$8.9 million in 2024.